JP2020506190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506190A5 JP2020506190A5 JP2019541430A JP2019541430A JP2020506190A5 JP 2020506190 A5 JP2020506190 A5 JP 2020506190A5 JP 2019541430 A JP2019541430 A JP 2019541430A JP 2019541430 A JP2019541430 A JP 2019541430A JP 2020506190 A5 JP2020506190 A5 JP 2020506190A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- antibody
- pharmaceutical composition
- diuretic
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001005 Interleukin-6 Proteins 0.000 claims description 84
- 239000002934 diuretic Substances 0.000 claims description 27
- 230000001882 diuretic effect Effects 0.000 claims description 27
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000002171 loop diuretic Substances 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 133
- 102000004889 Interleukin-6 Human genes 0.000 description 82
- 239000000427 antigen Substances 0.000 description 36
- 108091007433 antigens Proteins 0.000 description 36
- 102000036639 antigens Human genes 0.000 description 36
- 239000012634 fragment Substances 0.000 description 36
- 239000005557 antagonist Substances 0.000 description 31
- 238000005259 measurement Methods 0.000 description 16
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 11
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 8
- 230000029142 excretion Effects 0.000 description 8
- 102000052611 human IL6 Human genes 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 241000219495 Betulaceae Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 229960000074 biopharmaceutical Drugs 0.000 description 6
- -1 desernotinib Chemical compound 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229960003323 siltuximab Drugs 0.000 description 6
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 4
- 239000004012 Tofacitinib Substances 0.000 description 4
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 229950000971 baricitinib Drugs 0.000 description 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229950002507 elsilimomab Drugs 0.000 description 2
- 229950006663 filgotinib Drugs 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 2
- 229950011410 pacritinib Drugs 0.000 description 2
- HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 2
- 229950000088 upadacitinib Drugs 0.000 description 2
- 229940039916 xeljanz Drugs 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 101710158332 Diuretic hormone Proteins 0.000 description 1
- 101710204261 Diuretic hormone class 2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022155644A JP2023002563A (ja) | 2017-02-01 | 2022-09-29 | 利尿薬耐性の治療 |
| JP2024139009A JP2024164113A (ja) | 2017-02-01 | 2024-08-20 | 利尿薬耐性の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453257P | 2017-02-01 | 2017-02-01 | |
| US62/453,257 | 2017-02-01 | ||
| PCT/US2018/016508 WO2018144773A1 (en) | 2017-02-01 | 2018-02-01 | Treatment of diuretic resistance |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155644A Division JP2023002563A (ja) | 2017-02-01 | 2022-09-29 | 利尿薬耐性の治療 |
| JP2024139009A Division JP2024164113A (ja) | 2017-02-01 | 2024-08-20 | 利尿薬耐性の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506190A JP2020506190A (ja) | 2020-02-27 |
| JP2020506190A5 true JP2020506190A5 (https=) | 2021-12-16 |
| JP7630906B2 JP7630906B2 (ja) | 2025-02-18 |
Family
ID=63040146
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541430A Active JP7630906B2 (ja) | 2017-02-01 | 2018-02-01 | 利尿薬耐性の治療 |
| JP2022155644A Withdrawn JP2023002563A (ja) | 2017-02-01 | 2022-09-29 | 利尿薬耐性の治療 |
| JP2024139009A Pending JP2024164113A (ja) | 2017-02-01 | 2024-08-20 | 利尿薬耐性の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155644A Withdrawn JP2023002563A (ja) | 2017-02-01 | 2022-09-29 | 利尿薬耐性の治療 |
| JP2024139009A Pending JP2024164113A (ja) | 2017-02-01 | 2024-08-20 | 利尿薬耐性の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11203636B2 (https=) |
| EP (1) | EP3576790A4 (https=) |
| JP (3) | JP7630906B2 (https=) |
| KR (2) | KR20200012823A (https=) |
| CN (1) | CN110913900A (https=) |
| AU (2) | AU2018214554C1 (https=) |
| CA (1) | CA3051865C (https=) |
| IL (2) | IL268294B2 (https=) |
| MX (1) | MX390722B (https=) |
| SG (2) | SG10201912128SA (https=) |
| TW (2) | TWI850514B (https=) |
| WO (1) | WO2018144773A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991637C (en) | 2015-07-31 | 2022-07-05 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| KR20200012823A (ko) | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
| EP3735421A4 (en) | 2018-01-05 | 2021-09-22 | Corvidia Therapeutics, Inc. | METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION |
| JP7701273B2 (ja) | 2019-05-01 | 2025-07-01 | ノヴォ ノルディスク アー／エス | 抗ｉｌ－６抗体製剤 |
| CN114375205A (zh) * | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| AR122933A1 (es) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | Métodos para tratar la enfermedad cardiovascular |
| TWI907583B (zh) * | 2020-12-11 | 2025-12-11 | 大陸商江蘇恒瑞醫藥股份有限公司 | Jak抑制劑在腎臟疾病中的應用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0399429A1 (en) | 1989-05-22 | 1990-11-28 | Toray Industries, Inc. | Anti-human interleukin-6 monoclonal antibody |
| JP2881311B2 (ja) | 1989-07-28 | 1999-04-12 | 味の素株式会社 | 抗ヒトｂｃｄｆモノクローナル抗体及びそれを用いたヒトｂｃｄｆの定量法 |
| AU6808194A (en) | 1993-05-31 | 1994-12-20 | Chugai Seiyaku Kabushiki Kaisha | Reconstructed human antibody against human interleukin-6 |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| DE69534075T2 (de) * | 1994-06-07 | 2005-07-21 | Chugai Seiyaku K.K. | Vorbeugungs- und heilmittel für erkrankungen, die durch fibrin- oder thrombusbildung hervorgerufen werden |
| US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| JPH1066582A (ja) | 1996-08-27 | 1998-03-10 | Tosoh Corp | Ｉｌ−６のヘリックスｄ領域を認識する抗体の遺伝子断片等 |
| CN100374159C (zh) | 1998-03-17 | 2008-03-12 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
| US6395273B1 (en) | 1998-06-10 | 2002-05-28 | Promega Corporation | Prevention and treatment of inflammatory bowel disease |
| JP2002543147A (ja) | 1999-04-29 | 2002-12-17 | ノボ ノルディスク アクティーゼルスカブ | ブラジキニン放出の阻害におけるヘパリン結合アンタゴニストの使用 |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| AU2000279624A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| PL374259A1 (en) | 2001-06-28 | 2005-10-03 | Pliva D.D. | Novel heterocyclic compounds as selective bacterial dhfr inhibitors and their uses thereof |
| PT2308888T (pt) | 2001-11-14 | 2017-05-03 | Janssen Biotech Inc | Anticorpos anti-il-6, composições, métodos e utilizações |
| CA2467521A1 (en) | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
| FR2833011B1 (fr) | 2001-12-04 | 2004-10-29 | Univ Claude Bernard Lyon | Nouvelle proteine a activite inhibitrice de l'il-6 |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| KR100442281B1 (ko) | 2002-08-26 | 2004-08-02 | 엘지전자 주식회사 | 홈 네트워크 시스템의 제어 방법 |
| US7482436B2 (en) | 2002-08-30 | 2009-01-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of antibody |
| EP1572103A4 (en) | 2002-11-15 | 2008-02-13 | Centocor Inc | ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| JP4960096B2 (ja) | 2003-09-22 | 2012-06-27 | ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−６の生物学的効果を減じる化合物の使用 |
| ATE464908T1 (de) | 2004-02-11 | 2010-05-15 | Warner Lambert Co | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern |
| WO2006072954A2 (en) | 2005-01-05 | 2006-07-13 | Compugen Ltd. | Novel il-6 polynucleotides encoding variant il-6 polypeptides and methods using same |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| ES2694247T3 (es) | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| AR058135A1 (es) | 2005-10-21 | 2008-01-23 | Chugai Pharmaceutical Co Ltd | Agentes para el tratamiento de cardiopatias |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| TW200803894A (en) | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
| SI1960430T1 (sl) | 2005-12-09 | 2015-01-30 | Ucb Pharma, S.A. | Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6 |
| WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| ATE550353T1 (de) | 2005-12-30 | 2012-04-15 | Merck Patent Gmbh | Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper |
| US20110059101A9 (en) | 2006-03-13 | 2011-03-10 | Ablynx N.V. | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling |
| US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| CN101563365B (zh) | 2006-08-03 | 2012-10-31 | 瓦西尼斯公司 | 抗-il-6单克隆抗体及其用途 |
| CA2667466A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| ES2433380T3 (es) | 2006-11-30 | 2013-12-10 | Medimmune Limited | Anticuerpos específicos para el complejo de interleucina 6 y el receptor de interleucina 6 |
| JP4966647B2 (ja) | 2006-12-27 | 2012-07-04 | 矢崎総業株式会社 | 電気接続箱のシール構造 |
| CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| TW201307390A (zh) | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法 |
| AU2008247382B2 (en) | 2007-05-07 | 2014-06-05 | Medimmune, Llc | Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| KR20170036814A (ko) | 2007-05-21 | 2017-04-03 | 앨더바이오 홀딩스 엘엘씨 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20090238825A1 (en) | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| WO2008156807A2 (en) | 2007-06-19 | 2008-12-24 | The Johns Hopkins University | Antithrombotic agents and methods of use thereof |
| US20110008329A1 (en) | 2007-06-26 | 2011-01-13 | Medlmmune, Llc | Methods of Treating RSV Infections And Related Conditions |
| US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8529897B2 (en) | 2007-08-16 | 2013-09-10 | Carnegie Mellon University | Inflammation-regulating compositions and methods |
| US20100203009A1 (en) | 2007-10-02 | 2010-08-12 | The Uab Research Foundation | Pathway for Th-17 Cell Development and Methods Utilizing Same |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| MX2010012031A (es) | 2008-05-13 | 2011-01-20 | Novimmune Sa | Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos. |
| US8277804B2 (en) | 2008-05-21 | 2012-10-02 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| KR20110112307A (ko) | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ６의 길항제 |
| CN104119438A (zh) | 2009-01-29 | 2014-10-29 | 米迪缪尼有限公司 | 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用 |
| CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| WO2012012531A2 (en) | 2010-07-20 | 2012-01-26 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods featuring il-6 and il-21 antagonists |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| KR20190120439A (ko) | 2010-11-08 | 2019-10-23 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| US9560839B2 (en) | 2010-11-17 | 2017-02-07 | Technion Research And Development Foundation Ltd. | Physico-chemical process for removal of nitrogen species from recirculated aquaculture systems |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| MX342810B (es) | 2011-03-03 | 2016-10-13 | Apexigen Inc | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| AU2013334788A1 (en) * | 2012-10-22 | 2015-06-04 | Henry Ford Health Systems | Methods for reducing risks associated with heart failure and factors associated therewith |
| CN104768578A (zh) | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| CN104903349B (zh) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
| MX373894B (es) | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| JP2016064985A (ja) * | 2013-02-01 | 2016-04-28 | 国立大学法人大阪大学 | 拡張性心不全を治療または診断するための組成物およびその利用 |
| WO2014152006A2 (en) | 2013-03-15 | 2014-09-25 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
| US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| US20160130340A1 (en) | 2013-10-07 | 2016-05-12 | Alderbio Holdings Llc | Dosing regimens using anti-il-6 antibodies for the treatment of rheumatoid and psoriatic arthritis |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| CA2991637C (en) | 2015-07-31 | 2022-07-05 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| KR20200012823A (ko) | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
| EP3735421A4 (en) | 2018-01-05 | 2021-09-22 | Corvidia Therapeutics, Inc. | METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION |
-
2018
- 2018-02-01 KR KR1020197025663A patent/KR20200012823A/ko not_active Ceased
- 2018-02-01 MX MX2019008966A patent/MX390722B/es unknown
- 2018-02-01 TW TW110100113A patent/TWI850514B/zh active
- 2018-02-01 SG SG10201912128SA patent/SG10201912128SA/en unknown
- 2018-02-01 KR KR1020257005525A patent/KR20250029283A/ko active Pending
- 2018-02-01 CA CA3051865A patent/CA3051865C/en active Active
- 2018-02-01 JP JP2019541430A patent/JP7630906B2/ja active Active
- 2018-02-01 EP EP18747692.4A patent/EP3576790A4/en active Pending
- 2018-02-01 AU AU2018214554A patent/AU2018214554C1/en active Active
- 2018-02-01 WO PCT/US2018/016508 patent/WO2018144773A1/en not_active Ceased
- 2018-02-01 CN CN201880020541.7A patent/CN110913900A/zh active Pending
- 2018-02-01 SG SG11201906852XA patent/SG11201906852XA/en unknown
- 2018-02-01 TW TW107103707A patent/TWI716668B/zh active
- 2018-02-01 US US16/482,038 patent/US11203636B2/en active Active
-
2019
- 2019-07-28 IL IL268294A patent/IL268294B2/en unknown
-
2021
- 2021-03-04 IL IL281274A patent/IL281274A/en unknown
- 2021-11-04 US US17/519,082 patent/US12600773B2/en active Active
-
2022
- 2022-08-26 AU AU2022221557A patent/AU2022221557A1/en not_active Abandoned
- 2022-09-29 JP JP2022155644A patent/JP2023002563A/ja not_active Withdrawn
-
2024
- 2024-08-20 JP JP2024139009A patent/JP2024164113A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506190A5 (https=) | ||
| US20200031937A1 (en) | Vedolizumab for the treatment of fistulizing crohn's disease | |
| CN105392800A (zh) | 抗cxcl1、cxcl7和cxcl8抗体及其应用 | |
| CA2786435A1 (en) | Methods for treating breast cancer | |
| JP2020515247A (ja) | 抗ｏｘ４０抗体およびその使用 | |
| JP2024028805A (ja) | がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療 | |
| HK1204926A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| CN112955748A (zh) | 治疗癌症的方法 | |
| US20210187105A1 (en) | Combination therapy of anti-mif antibodies and glucocorticoids | |
| CN113227137A (zh) | IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途 | |
| CA3251417A1 (en) | METHODS FOR REDUCING PERFUSION-RELATED REACTIONS IN PATIENTS TREATED WITH EGFR/MET BISPECIFIC ANTIBODIES | |
| WO2022215017A1 (en) | Treatments for prurigo nodularis | |
| van Strien et al. | Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence | |
| CN114423455A (zh) | 用于治疗系统性硬化症的药物组合物 | |
| CN120344271A (zh) | 抗her2抗体药物偶联物治疗乳腺癌 | |
| JP2023071904A (ja) | カナキヌマブの使用 | |
| WO2026094824A1 (ja) | Ｐａｄ阻害剤の自己免疫性関節炎の治療または予防のための使用 | |
| US8003102B2 (en) | Anti-CXCR4 antibodies | |
| JP2023527926A (ja) | 静脈内投与と関連する抗体耐容性の改善 | |
| US20250019447A1 (en) | Combination therapy for treatment of cancer | |
| KR102926992B1 (ko) | Tctp에 특이적으로 결합하는 항체 및 이의 용도 | |
| JP7280259B2 (ja) | 非アルコール性脂肪性肝炎の抗ｈｕＴＮＦＲ１治療 | |
| Milano et al. | Recent Patents on Xolair, a New Monoclonal Drug Anti-IgE Antibody for the Treatment of Allergic Asthma | |
| WO2026038160A1 (en) | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies | |
| Morgado | Internship Reports and Monograph Entitled “Pharmacokinetic Monitorization of Monoclonal Antibodies: The Example of Infliximab in Inflammatory Bowel Diseases” |